National Clinical Research Center for Eye Diseases gave recommendations around eight clinical problems and formed China's guidelines for the clinical diagnosis and treatment of AMD. With the implementation of these guidelines, we can standardize the diagnosis, treatment, prevention and follow up of AMD in China. (This article was published ahead of print on the official website of Chinese Journal of Ophthalmology on April 6, 2023)

Key words Macular degeneration; Practice guidelines as topic; Evidence based medicine

Np_arɣac esɣbcjɣlc pceɣqrp_rɣml8 Practice Guideline Registration for Transparency, IPGRD 2021CN111

ă ɔ age related macular degeneration AMD e Ң Ό ν ε ʐ ѫ [1] 2040 Ã AMD ᾰ́ 2.88 к Ʒ [2 3] в ο 70 ᘐ ɕ e AMD δ 20.2% [3] ο e ѫ ⅞ ' ˛ AMD Ϛ ǵ ɕ ╖ в 2013 ο Beckmann AMD ŏ ή AMD ŏ δ ɔ ɜ ɔ ɜ AMD ɜX AMD ᴎ AMD [4] в ă Age related Eye Disease Study AREDS AMD ŏ ΆA ‴ Beckmann ŏ ч [5] в AMD ẇ ŏ δ ئ ہ geographic atrophy GA ᴎ AMD AMD Ϛ δ Ό AMD ▉ AMD 10%~20% [1] в Ẉ Ḍ optical coherence tomography OCT ᴎ AMD ầ ο AMD ᴎ̂ ả Љ 2020 Ë AMD └ macular neovascularization MNV ŏ ѥ OCT ہ Ḍ X MNV ᴎ Ң Ẹ ŏ δ 1 ⅔ ᴎ 3 ѥ [6] в Ë AMD ă ŏ ѥ 10 Ḍ ᴎ Ϛ ҭ Ẉ Ḍ optical coherence tomography angiography OCTA Ḍ δ AMD ᴎ W Ë ᴎ ę [7 8] ǵ AMD ╤ Ẋ ɱ ᴎ ´ ê ѫ vascular endothelial growth factor VEGF ´ ᴎ ҭ ˊˆ ᴎ Ϛ δ W Ë δ [9 11] в ǵ ΆA ɜT ɱ ⅞ ў Љ ˊˆ ´ ᴎ ┘ Ό Ë Ϛ ή ě Ë в ѽ ο ┘ Љ AMD ŏ ѥ ɜ ᴎ ´ Ẅ ŏ ┘ ‴ Ẹ ë E ΄ ┘ AMD ǵ ~ ئ └ ɜ ˜ ┘ AMD ψ ᘐ ẇ ᴎ ˊˆ ѫ AMD K ' ᴎ ځ в ɲ Љ δ Ë ئ ο ┘ ă ή ě X ⅄ ┘ Ь ŏ Ь ɜ X ο ┘ ╞ Ь ┘ ŏ Ь ‴ ο ή ┘ X ɲ Љ ┘ ´ ο ╤ ᴎ ο Ь ҭ ǵ 2013 ц X ο ă ɔ ή ħ [12] ɲ ɕ Љ 2023 ΆĄ ο AMD ή ╤ ᘐ Љ ο AMD ɜ ɜ ᴎ ě в h ɜ ╤ ΆĄ h ╤ ΆĄ ˆ ᴎ ╤ X ⅄ ┘ Ь ŏ Ь ᴎ X ο ┘ ╞ Ь ┘ ŏ Ь ҭ ΆĄ ᴎ Θ

GRADE grading of recommendations assessment development and evaluation ŏ ç ɜΆĄ ‴ Θ 1 [13 16] m GRADE X W в ╤ ‴ ΆĄ ˆ Ώ ▲ world health organization WHO ҭ ц Ώ ▲ ╤ ΆĄ Ỏ ħ ɔ ο ┘ Ό ή ╤ σ [17] ᘐ ẇ 2016 X ⅄ ┘ Ь ҭ ц ΆĄ /ת ɣ ή ╤ ɤ ɲ ẇ ħ [18] в ╤ ǵ ο ╤ Ỏ ‴ ⅞ ' http // x uldeline registr 2000 z 10

ŭ δ ϰ ψ 2 в ⌟
ώ ά Θ d
v Ω
δ ϰ υ Ω δ ψ 15 16 в
ў Ă м ⌟ у
ў ψ
Љ м ⌟ ă у 1 в
Ї

AMD ƥ ă в
ε в е δ Ψ J A

ɜ ϰ Б

в Ɔ ∓
Ί ϰ Ί в
Ă
Ί ϰ ⌟

2. randomized controlled trial RCT RCT RCT Cochrane [19] RCT Newcastle Ottawa Scale Newcastle Ottawa Scale NOS

AMD 55~59
3.5% 85 17.6%
AMD 0.1% 9.8%[27]

AMD
AMD
AMD
[28,29]
12.3% 7.4%
7.5%
GA
AMD
AMD
polypoidal choroidal vasculopathy PCV
[30]
0.3%±0.1%[31]
PCV
AMD 22.3%~43.4%[32,33]

1. AMD
AMD
[34]
Y402H
ARMS2 HTRA1
[35,38]
AMD
AMD
[39]

2. AMD
AMD
[34,40]
AMD
[40]

3.
[41,42]
AMD
[43]
AMD

AMD 2 4. subretinal drusenoid deposit SDD reticular pseudodrusen RPD RPE FFA ICGA SDD RPE SDD AMD SDD [51] AMD [53] SDD GA RPE Bruch RPE [54] 2 Age related Eye Disease Study 2 AREDS2 GA 0.29 mm/ GA 0.28 mm/ [55] BMES Rotterdam GA 1.09 mm²/ [56] GA CNV [57] GA [55] AMD X Bruch RPE VEGF placental growth factor PIGF platelet derived growth factor PDGF tissue inhibitor of metalloproteinase TIMP [58] [59] ICGA PED [60] AMD

AREDS AMD AMD 1. AMD [1] 2. AMD <63 μm 63~ 124 μm RPE [1] 3. AMD RPE [6] 63~ 124 μm 1 T ≥125 μm [1] 4. AMD MNV intraretinal fluid IRF subretinal fluid SRF PED [1] CNV CNV <200 μm ≥200 μm FFA CNV 50% CNV [61] ICGA CNV FFA FFA CNV ICGA [h] 1 CNV CNV CNV ≤1 diameter of optic disc DD

2 CNV CNV W

>1 DD W CNV 3

CNV MNV

AMD AMD X retinal

angiogmatous proliferation RAP

AMD X

CNV

1 MNV FFA RPE ICGA PCV ICGA 2 MNV FFA ICGA PCV MNV FFA ICGA OCT AMD OCT B 1 MNV OCT RPE X PED SRF IRF PCV OCT Bruch PED 2 MNV OCT RPE X PED SRF IRF 3 MNV RAP OCT PED IRF OCTA OCTA OCTA OCTA AMD FFA OCTA 91% 73% PCV OCTA 79% 72% OCT OCTA 84% 67% RAP FFA ICGA OCTA OCTA


/

AREDS X

C 500 mg E 400 IU

15 mg

1 0.5 mg/ 3 T
1 3+ 3 T
3 T 1
0.5 mg/ PRN 3+PRN [91]
AMD
X Aurora X
0.5 mg 0.5 mg/ 2 mg
2 mg/ 3 T
1 2 T E PRN
E 12 T E
14.31 0.5 mg X 3+PRN E 9.31 0.5 mg
X 3+ E 12.42 2 mg X 3+PRN E
15.43 T 2 mg X 3+ E
AMD
[92] 0.5 mg/
AMD X
Phoenix X 3+ 3 T
12 T BCVA
9.98 T 3+ 3 T
AMD



factors study group[J]. Arch Ophthalmol, 2000, 118(3): 351 358. DOI: 10.1001/archopht.118.3.351.

[43] Klein R, Deng Y, Klein BE, et al. Cardiovascular disease, its risk factors and treatment, and age related macular degeneration: women's health initiative sight exam ancillary study[J]. Am J Ophthalmol, 2007, 143(3): 473 483. DOI: 10.1016/j.ajo.2006.11.058.

[44] Sangiovanni JP, Agrón E, Meleth AD, et al. Omega 3 Long chain polyunsaturated fatty acid intake and 12 y incidence of neovascular age related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the age related eye disease study[J]. Am J Clin Nutr, 2009, 90(6): 1601 1607. DOI: 10.3945/ajcn.2009.27594.

[45] Chong EW, Kreis AJ, Wong TY, et al. Dietary omega 3 fatty acid and fish intake in the primary prevention of age related macular degeneration: a systematic review and meta analysis[J]. Arch Ophthalmol, 2008, 126(6): 826 833. DOI: 10.1001/archopht.126.6.826.

[46] Clemons TE, Milton RC, Klein R, et al. Risk factors for the incidence of advanced age related macular degeneration in the age related eye disease study (AREDS) AREDS report no. 19[J]. Ophthalmology, 2005, 112(4): 533 539. DOI: 10.1016/j.ophtha.2004.10.047.

[47] Hogg RE, Woodside JV, McGrath A, et al. Mediterranean diet score and its association with age related macular degeneration: the European eye study[J]. Ophthalmology, 2017, 124(1): 82 89. DOI: 10.1016/j.ophtha.2016.09.019.

[48] Merle B, Colijn JM, Cougnard Grégoire A, et al.

and CNV area (CNV A) in patients with type 1 and type 2 nAMD[C]. 2017 ARVO Annual Meeting, Baltimore, MD, 2017. Baltimore: Association for Research in Vision and Ophthalmology, 2017.

[70] Nikolopoulou E, Lorusso M, Micelli Ferrari L, et al. Optical coherence tomography angiography versus dye angiography in age related macular degeneration: sensitivity and specificity analysis[J]. Biomed Res Int, 2018, 2018: 6724818. DOI: 10.1155/2018/6724818.

[71] Soomro T, Talks J. The use of optical coherence tomography angiography for detecting choroidal neovascularization, compared to standard multimodal imaging[J]. Eye (Lond), 2018, 32(4): 661 672. DOI: 10.1038/eye.2018.2.

[72] Usman M, Iqbal K, Ali MH, et al. Features and diagnostic accuracy of optical coherence tomography angiography in neovascular age related macular degeneration[J]. Cureus, 2019, 11(12): e6485. DOI: 10.7759/cureus.6485.

[73] Ghanchi FD, Fulcher C, Madanat Z, et al. Optical coherence tomography angiography for identifying choroidal neovascular membranes: a masked study in clinical practice[J]. Eye (Lond), 2021, 35(1): 134 141. DOI: 10.1038/s41433 020 01285 0.

[74] de Carlo TE, Kokame GT, Kaneko KN, et al. Sensitivity and specificity of detecting polypoidal choroidal vasculopathy with en face optical coherence tomography and optical coherence tomography angiography[J]. Retina, 2019, 39(7): 1343 1352. DOI: 10.1097/IAE.0000000000002139.

[75] Huang YM, Hsieh MH, Li AF, et al. Sensitivity, specificity, and limitations of optical coherence tomography angiography in diagnosis of polypoidal choroidal vasculopathy[J]. J Ophthalmol, 2017, 2017: 3479695. DOI: 10.1155/2017/3479695.

[76] Mao J, Cheng D, Lin J, et al. Evaluating retinal angiomatous proliferation with optical coherence tomography angiography[J]. Ophthalmic Surg Lasers Imaging Retina, 2020, 51(3): 136 144. DOI: 10.3928/23258160 20200228 02.

[77] Dansingani KK, Naysan J, Freund KB. En face OCT angiography demonstrates flow in early type 3 neovascularization (retinal angiomatous proliferation) [J]. Eye (Lond), 2015, 29(5): 703 706. DOI: 10.1038/eye.2015.27.

[78] Age Related Eye Disease Study 2 Research Group. Lutein+ zeaxanthin and omega 3 fatty acids for age related macular degeneration: the age related eye disease study 2 (AREDS2) randomized clinical trial[J]. JAMA, 2013, 309(19): 2005 2015. DOI: 10.1001/jama.2013.4997.

[79] Newsome DA, Swartz M, Leone NC, et al. Oral zinc in macular degeneration[J]. Arch Ophthalmol, 1988, 106(2): 192 198. DOI: 10.1001/archopht.1988.01060130202026.

[80] Stur M, Tittl M, Reitner A, et al. Oral zinc and the second eye in age related macular degeneration[J]. Invest Ophthalmol Vis Sci, 1996, 37(7): 1225 1235.

[81] , Ỳ Ķ, . ¨ ǎ ɔ ´ Ĩ [J]. ο , 2017, 17(11): 2109 2111. DOI: 10.3980/j.issn.1672 5123.2017.11.28.

[82] Richer S, Stiles W, Statkute L, et al. Double masked, placebo controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age related macular degeneration: the veterans last study (lutein antioxidant supplementation trial) [J]. Optometry, 2004, 75(4): 216 230. DOI: 10.1016/s1529 1839(04)70049 4.

[83] Ma L, Yan SF, Huang YM, et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age related macular degeneration[J]. Ophthalmology, 2012, 119(11): 2290 2297. DOI: 10.1016/j.ophtha.2012.06.014.

[84] Piermarocchi S, Saviano S, Parisi V, et al. Carotenoids in age related maculopathy Italian study (CARMIS): two year results of a randomized study[J]. Eur J Ophthalmol, 2012, 22(2): 216 225. DOI: 10.5301/ejo.5000069.

[85] Beatty S, Chakravarthy U, Nolan JM, et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age related macular degeneration[J]. Ophthalmology, 2013, 120(3): 600 606. DOI: 10.1016/j.ophtha.2012.08.040.

[86] Murray IJ, Makridaki M, van der Veen RL, et al. Lutein supplementation over a one year period in early AMD might have a mild beneficial effect on visual acuity: the clear study[J]. Invest Ophthalmol Vis Sci, 2013, 54(3): 1781 1788. DOI: 10.1167/iovs.12 10715.

[87] Souied EH, Delcourt C, Querques G, et al. Oral docosahexaenoic acid in the prevention of exudative age related macular degeneration: the nutritional AMD treatment 2 study[J]. Ophthalmology, 2013, 120(8): 1619 1631. DOI: 10.1016/j.ophtha.2013.01.005.

[88] Huang YM, Dou HL, Huang FF, et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age related macular degeneration: a randomised, double blind, placebo controlled trial[J]. Br J Ophthalmol, 2015, 99(3): 371 375. DOI: 10.1136/bjophthalmol 2014 305503.

[89] Piatti A, Croce A, Mazzacane D, et al. Effect of 2 year nutritional supplementation on progression of age related macular degeneration[J]. Eur J Ophthalmol, 2020, 30(2): 376 381. DOI: 10.1177/1120672119836007.

[90] Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age related macular degeneration[J]. N Engl J Med, 2006, 355(14): 1432 1444. DOI: 10.1056/NEJMoa062655.

[91] Lu X, Sun X. Profile of conbercept in the treatment of neovascular age related macular degeneration[J]. Drug Des Devel Ther, 2015, 9: 2311 2320. DOI: 10.2147/DDDT.S67536.

[92] Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age related macular degeneration: results from a 12 month randomized phase 2 study: AURORA study[J]. Ophthalmology, 2014, 121(9): 1740 1747. DOI: 10.1016/j.ophtha.2014.03.026.

[93] Li X, Chen Y, Zhang J, et al. Intravitreal aflibercept versus photodynamic therapy in Chinese patients with neovascular age related macular degeneration: outcomes of the SIGHT Study[J]. J Ocul Pharmacol Ther, 2017, 33(6): 435 444. DOI: 10.1089/jop.2016.0071.

[94] Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of ranibizumab and aflibercept on best corrected visual acuity in treat and extend for neovascular age related macular degeneration: a randomized clinical Trial[J]. JAMA Ophthalmol, 2019, 137(4): 372 379. DOI: 10.1001/jamaophthalmol.2018.6776.

[95] Wykoff CC, Ou WC, Brown DM, et al. Randomized trial of treaĎ q l

ranibizumab[J]. 0.566 0 Td [>-10<004107]TJ 0.B

predicting loss to follow up[J]. Am J Ophthalmol, 2020, 210: 86 96. DOI: 10.1016/j.ajo.2019.10.012.

[144] Ehlken C, Wilke T, Bauer Steinhusen U, et al. Treatment of neovascular age related macular degeneration patients with vascular endothelial growth factor inhibitors in everyday practice: identification of health care constraints in Germany the PONS æstudy[J]. Retina, 2018, 38(6): 1134 1144. DOI: 10.1097/IAE.0000000000001681.

[145] Parikh 4 •"r!Ðrá€rš Õb1iPÒ' Ü…€rq!U"0ÐÒ' Þžqqg!1Ð ' ¢q€ráqáQ'ao!Â(!•5%"ƒ‹Ÿ “p™—‰Ƒ•™°èpƒ‡ž–Œp– ' •š